Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Document › Details

BioIndustry Assocation (BIA). (8/30/17). "Press Release: BIA Responds to Life Sciences Industrial Strategy".

Region Region United Kingdom (GB)
Organisations Organisation BioIndustry Association (BIA) (GB)
  Organisation 2 United Kingdom (GB) (govt)
Products Product LIFE SCIENCES
  Product 2 business development (state/region)
Person Person Bates, Steve (BIA 201211 CEO)

The BioIndustry Association (BIA) welcomes the publication of the Life Sciences Industrial Strategy. Professor Sir John Bell, Regius Professor of Medicine at Oxford, has led the development of this report to government, with input from across the life sciences ecosystem, including the Life Sciences Industrial Strategy Board.

BIA CEO and Life Sciences Industrial Strategy Board member Steve Bates said:

“It is fantastic to see the publication of a life sciences industrial strategy that can act as a springboard to an early sector deal for the life sciences industry. The BIA has long called for a revived industrial strategy to maintain and build investment into the UK and grow and scale the UK’s innovative bioscience companies. We stand ready to continue engagement with government to ensure that this strategy can pave the way for an impactful sector deal that can help deliver the BIA’s vision to establish the UK as the third global cluster for life sciences.”

Alongside the publication of the strategy, the government also announced a new £13m funding competition for a medicines manufacturing centre, a £66m investment in a vaccines development and manufacturing centre, a £30m investment in cell and gene therapy treatment centres, a £12m cell and gene therapy investment in Stevenage and £25m to support SMEs and boost innovation.

CEO Steve Bates added: “These new investments and funding competitions bring to life the calls the BIA has made, both individually and through collaborations such as the Medicines Manufacturing Industry Partnership, to grow our industry’s future. It is great to see SMEs front and centre in today’s announcements.”

The strategy provides a wide-ranging view on many of the issues that underpin the life sciences ecosystem, including discovery and translational science, NHS collaboration, manufacturing and skills. It also challenges the sector to engage further with the opportunities in healthcare presented by new technology through the proposed Health Advanced Research Programme (HARP).

The strategy will be launched today at Birmingham’s Institute of Translational Medicine by Sir John Bell, alongside Secretary of State for Health Rt Hon Jeremy Hunt MP and Secretary of State for Business, Energy and Industrial Strategy Rt Hon Greg Clark MP.

BIA Chair Jane Osbourn will represent the BIA at this launch and said: “For the sector to achieve its potential and ambition, a sea change in the levels of scale-up capital and fiscal support is required. It is great to see many of the necessary actions the BIA has called for in this strategy, from reform of Entrepreneurs Relief to making R&D tax credits work better for SMEs. These recommendations, alongside the focus of the forthcoming Patient Capital Review, provide a great foundation to take the UK’s life sciences sector to the next level.”


Notes to editors

The government press release contains the below statement from a cross-section of industry and trade association members of the Life Sciences Industrial Strategy Board said, including the BIA:

“We welcome the publication of the Life Sciences Industrial Strategy, led by Sir John Bell. The Strategy and Board demonstrate the breadth and vibrancy of the life sciences ecosystem in the UK, the importance of collaboration across the sector, the critical role of the NHS in delivering the development and use of new medical technologies, and the contribution of our sector to the UK economy.

The Strategy provides a holistic and collaborative framework to realise the many exciting opportunities in the future of life sciences in the UK and is a positive first step to cementing the success of our sector.

This should provide the springboard for an early Sector Deal for the life sciences sector, including the NHS and other stakeholders; this will be vital to ensuring that the recommendations set out in this Strategy are fully implemented.

As the UK leaves the EU, collaboration with, and support from Government is more important than ever to maintaining the UK’s position as a global life sciences ecosystem.”

This quote was provided by a cross-section of Life Sciences Industrial Strategy Board members (Association of British Healthcare Industries, Association of the British Pharmaceutical Industry, AstraZeneca, BioIndustry Association, GSK, Immunocore Ltd, Johnson & Johnson, MSD, Northern Health Science Alliance Ltd.) The full Board brought together representation from across the sector, including industry, academia and charities.


Pamela Learmonth, Director of Public Affairs and Communications
Tel: 020 7630 2188 and

About the UK BioIndustry Association (BIA)

Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.

For further information, please go to and

Record changed: 2017-09-06


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for BioIndustry Association (BIA) (GB)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px

» top